Evidence map›Paper›PMID 11477134›Full record

ReviewMolecular pathology : MP2001

What we could do now: molecular pathology of gynaecological cancer.

C S Herrington

Abstract readReview
In one paragraph

Review in Molecular pathology : MP, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2006
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

C S HerringtonDepartment of Pathology, Duncan Building, Royal Liverpool University of Hospital, Daulby Street, Liverpool L69 3GA, UK. c.s.herrington@liv.ac.uk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.

Indexed as

AdultDNA, ViralEndometrial HyperplasiaEndometrial NeoplasmsFemaleGenes, p53Genetic MarkersGenital Neoplasms, FemaleHumansMesenchymomaOvarian NeoplasmsPapillomaviridaePredictive Value of TestsPrognosisSarcomaUterine Cervical NeoplasmsDNA, ViralGenetic Markers

Identifiers

PMID11477134
PMCPMC1187070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.